Recurrence-Related Factors in Early Stage Endometrial Cancer

Abstract

Objective: The main objective of this study is to identify clinical and pathological factors associated with recurrence in patients diagnosed with early-stage (stage I–II) endometrial cancer.
Methods: A total of 98 patients diagnosed with stage I–II endometrial cancer who underwent surgical treatment at a single center between 2017 and 2021 were retrospectively analyzed. The patients’ clinical and pathological characteristics, the adjuvant therapies administered, and follow-up outcomes were evaluated. Factors associated with recurrence were assessed using univariate analyses.
Results: The mean age of the patients was 59.8 years, and the mean tumor size was 3.58 cm. The mean follow-up period was 49.1 months. The recurrence rate was 8.2%. Five recurrences were identified as locoregional, and three as distant metastases. In univariate analyses, surgical type (p=0.015), adjuvant therapy (p=0.009), and histotype (endometrioid vs. non-endometrioid, p=0.016) were found to be associated with recurrence.
Conclusions: The recurrence rate in early-stage endometrial cancer was found to be low, consistent with the literature, and it was determined that 5 of the recurrences were locoregional in nature, while the remaining 3 were distant metastases. Although surgical type, histological type, and adjuvant therapy were identified as factors associated with recurrence in univariate analyses, there is a need for a detailed examination of these factors through multicenter studies involving larger patient cohorts.

Keywords

• Endometrial cancer
• Early stage
• Recurrence
• Prognostic factors

References

1. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7(1):88. doi:10.1038/s41572-021-00324-8.
2. Misirlioglu S, Guzel A, Gulec U, Gumurdulu D, Vardar M. Prognostic factors determining recurrence in early-stage endometrial cancer. Eur J Gynaecol Oncol. 2012;33(6):2012. doi:10.12892/ejgo201206610.
3. Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025: Featured Updates to the NCCN Guidelines®. J Natl Compr Canc Netw. 2025;23(8):284-91. doi:10.6004/jnccn.2025.0038.
4. Creutzberg CL, Van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys. 2015;91(3):530-9. doi:10.1016/j.ijrobp.2014.11.022.
5. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393-402. doi:10.1016/j.ygyno.2014.06.003.
6. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355(9213):1404-11. doi:10.1016/s0140-6736(00)02139-5.
7. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744-51. doi:10.1016/j.ygyno.2003.11.048.
8. Sorbe BG, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study—quality-of-life analysis. Int J Radiat Oncol Biol Phys. 2012;22(7):1281-8. doi:10.1016/j.ijrobp.2011.04.014.

9. Francis SR, Ager BJ, Do OA, Huang Y-HJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154(1):38-44. doi:10.1016/j.ygyno.2019.04.676.
10. De Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. doi:10.1016/S1470-2045(18)30079-2.
11. Takahashi K, Yunokawa M, Sasada S, Takehara Y, Miyasaka N, Kato T, et al. A novel prediction score for predicting the baseline risk of recurrence of stage I–II endometrial carcinoma. J Gynecol Oncol. 2018;30(1):e8. doi:10.3802/jgo.2019.30.e8.
12. Dou Y, Song K, Fu Y, Shen Y, Zhang C, Yao S, et al. Risk factors and prognosis of early recurrence in stage I–II endometrial cancer: a large-scale, multi-center, and retrospective study. Front Med (Lausanne). 2022;9:808037. doi:10.3389/fmed.2022.808037.
13. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial☆. Gynecol Oncol. 2003;89(2):201-9. doi:10.1016/s0090-8258(03)00126-4.
14. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens J-WM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631-e8. doi:10.1016/j.ijrobp.2011.04.013.
15. Yechieli R, Robbins JR, Schultz D, Munkarah A, Elshaikh MA. Vaginal recurrence more than 17 years after hysterectomy and adjuvant treatment for uterine carcinoma with successful salvage brachytherapy: a case report. Case Rep Oncol. 2011;4(1):242-5. doi:10.1159/000328076.
16. Bendifallah S, Ouldamer L, Lavoue V, Canlorbe G, Raimond E, Coutant C, et al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study Group. Gynecol Oncol. 2017;144(1):107-12. doi:10.1016/j.ygyno.2016.10.025.
17. Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215-24. doi:10.1158/1078-0432.ccr-15-2878.
18. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836-44. doi:10.1038/modpathol.2015.43.
19. Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423-e35. doi:10.1016/s1470-2045(25)00167-6.
20. Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, et al. Baseline risk of recurrence in stage I–II endometrial carcinoma. J Gynecol Oncol. 2017;29(1):e9. doi:10.3802/jgo.2018.29.e9.
21. Dunn EF, Geye H, Platta CS, Gondi V, Rose S, Bradley KA, et al. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecol Oncol. 2014;133(3):494-8. doi:10.1016/j.ygyno.2014.03.554.
22. Capozzi VA, Sozzi G, Rosati A, Restaino S, Gambino G, Cianciolo A, et al. Predictive score of nodal involvement in endometrial cancer patients: a large multicentre series. Ann Surg Oncol. 2022;29(4):2594-9. doi:10.1245/s10434-021-11083-x.
23. Ureyen I, Karalok A, Turkmen O, Kimyon G, Akdas YR, Akyol A, et al. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI?. Arch Gynecol Obstet. 2020;301(3):737-44. doi:10.1007/s00404-019-05418-z.
24. Nout RA, Bosse T, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation. Gynecol Oncol. 2012;126(3):466-73. doi:10.1016/j.ygyno.2012.05.012.
25. Barretina-Ginesta MP, Quindós M, Alarcón JD, Esteban C, Gaba L, Gómez C, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2021). Clin Transl Oncol. 2022;24(4):625-34. doi:10.1007/s12094-022-02799-7.
26. Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2020;383(21):2053-64. doi:10.1056/nejmra1514010.
27. Han KH, Kim HS, Lee M, Chung HH, Song YS. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB. Medicine (Baltimore). 2017;96(21):e6976. doi:10.1097/md.0000000000006976.
28. Jeppesen MM, Jensen PT, Hansen DG, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—A national cohort study. Eur J Cancer. 2016;69:51-60. doi:10.1016/j.ejca.2016.09.033.
29. Tortorella L, Restaino S, Zannoni GF, Vizzielli G, Chiantera V, Cappuccio S, et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021;32(2):e11. doi:10.3802/jgo.2021.32.e11.
30. Dane C, Bakir S. The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma. Afr Health Sci. 2019;19(4):3235-41. doi:10.4314/ahs.v19i4.47.
31. Pasternak M, Kessous R, Samueli B, Dreiher J, Meirovitz M, Davidesko S, et al. The prognostic importance of features of myometrial invasion in endometrial endometrioid carcinoma. Arch Gynecol Obstet. 2025;312(4):1215-24. doi:10.1007/s00404-025-08103-6.
32. Nwachukwu C, Baskovic M, Von Eyben R, Fujimoto D, Giaretta S, English D, et al. Recurrence risk factors in stage IA grade 1 endometrial cancer. J Gynecol Oncol. 2021;32(2):e22. doi:10.3802/jgo.2021.32.e22.
33. Stasenko M, Feit N, Lee SS, Shepherd C, Soslow RA, Cadoo KA, et al. Clinical patterns and genomic profiling of recurrent ‘ultra-low risk’endometrial cancer. Int J Gynecol Cancer. 2020;30(6):717-23. doi:10.1136/ijgc-2020-001241.
34. Wang C-J, Chao A, Yang L-Y, Hsueh S, Huang Y-T, Chou H-H, et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. Int J Gynecol Cancer. 2014;24(4):718-28. doi:10.1097/igc.0000000000000098.
35. Yoney A, Yildirim C, Bati Y, Unsal M. Low risk stage I endometrial carcinoma: prognostic factors and outcomes. Indian J Cancer. 2011;48(2):204-10. doi:10.4103/0019-509x.82895.
36. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynecol Obstet. 2009;105(2):107-8. doi:10.1016/j.ijgo.2009.02.009.
37. Cibas ES, Cytology D. Diagnostic principles and clinical correlates. Philadelphia; 2019.
38. Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer. 2003;88(2):245-50. doi:10.1038/sj.bjc.6600698.
39. Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128(1):77-82. doi:10.1016/j.ygyno.2012.09.026.
40. Lee B, Suh DH, Kim K, No JH, Kim YB. Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Jpn J Clin Oncol. 2016;46(8):711-7. doi:10.1093/jjco/hyw063.